Vimta Labs Limited

Vimta Labs Limited

489.45
INR
+0.85
(+0.17%)
17.67EPS
32.89P/E
26.25BMarket Cap
Nov 14Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
26.76
24.26
28.2
34.79
40.84
47.03
40.35
47.17
62.41
71.19
65.14
77.5
91.44
93.91
Basic EPS, GAAP
2.99
1.14
1.46
2.4
3.72
5.72
1.55
4.84
9.35
10.88
9.26
15.17
17.4
17.86
Free Cash Flow per Basic Share
1.84
1.74
-3.78
-3.61
2.05
5.11
1.93
0.93
4.6
8.62
-3.54
3.28
10.63
- -
Dividend per Share
0.35
1.17
0.6
0.6
- -
1.21
1.21
- -
1
1
1
1
1
- -
Book Value per Share
27.23
27.67
28.52
30.79
34.39
38.8
39.1
43.96
52.92
63.67
70.84
85.19
102.28
- -
Tangible Book Value per Share
27.23
27.67
28.52
30.79
34.39
38.8
37.84
42.7
48.64
59.65
68.79
83.75
101.18
- -
Basic Weighted Avg Shares
44
44
44
44
44
44
44
44
44
44
44
44
45
45
Sales/Revenue/Turnover
1,183
1,073
1,247
1,538
1,806
2,080
1,784
2,086
2,759
3,151
2,886
3,440
4,073
4,188
Operating Margin (%)
14.88
8.26
7.82
12.66
18.51
21.96
6.08
17.27
22.97
22.12
22.34
26.34
26.2
23.56
Depreciation Expense
94
111
103
96
157
197
209
231
233
307
342
357
438
465
Net Income, GAAP
132
51
64
106
164
253
68
214
413
482
410
673
775
797
Effective Tax Rate (%)
25.04
23.76
22.96
35.94
35.72
27.97
17.23
25
25.78
25.89
21.91
24.99
25.44
25.57
Profit Margin (%)
11.19
4.72
5.16
6.88
9.1
12.17
3.84
10.26
14.98
15.29
14.21
19.58
19.03
19.02
Working Capital
267
359
411
104
337
490
383
566
766
1,064
1,035
1,234
1,593
- -
LT Debt
- -
- -
160
181
195
116
54
142
127
99
91
32
16
- -
Total Equity
1,204
1,223
1,261
1,361
1,521
1,716
1,729
1,944
2,340
2,818
3,141
3,788
4,569
- -
Return on Invested Capital (%)
10.27
3.96
4.89
7.08
10.51
14.23
4.15
10.9
18.01
18.08
15.66
18.65
17.53
- -
Return on Capital (%)
10.81
4.26
5.1
7.03
10.38
14.15
4.4
10.54
17.55
17.76
13.4
18.98
18.38
- -
Return on Common Equity (%)
11.38
4.17
5.18
8.08
11.4
15.64
3.97
11.66
19.3
18.68
13.76
19.44
18.55
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
18
- -
LT Borrowings
- -
16
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
45
45
45
Market Capitalization
27,018
17,006
26,245

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
2,249
- -
Cash, Cash Equivalents & STI
- -
669
- -
Accounts Receivable, Net
- -
1,057
- -
Inventories
- -
299
- -
Total Current Liabilities
- -
655
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
18
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.92%
18.7%
20.6%
Free Cash Flow
24.92%
75.13%
225.15%
Net Income, GAAP
48.76%
34.82%
15.1%
Sales/Revenue/Turnover
13.43%
15.13%
18.4%
Total Cash Common Dividend
- -
- -
0.38%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
749
847
899
944
3,440
2026
976
1,018
986
1,092
4,073
2027
1,091
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.77
3.44
4.83
4.11
15.17
2026
4.25
4.46
3.96
4.73
17.4
2027
4.71
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
1
2027
- -
- -
- -
- -
- -

Company Description

CEO
Harita Vasireddi
Full Time Employees
1,384
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
Plot Nos. 141/2 & 142, IDA, Phase II Hyderabad TS India 500051
IPO Date
Sep 13, 1993
Website
vimta.com
Business
Vimta Labs Limited, founded in 1984 and headquartered in Hyderabad, India, operates as a leading contract research and testing organization primarily serving the pharmaceutical, biopharmaceutical, medical device, agrochemical, food, environmental, and electronics industries. The company offers a comprehensive range of services including drug discovery and development support, preclinical research, clinical research, cGMP and non-GMP analytical services, bioanalytical services, stability studies, microbiological testing, environmental monitoring, and regulatory compliance services. Vimta Labs also provides specialized testing solutions for food and beverages, water, electronic and electrical products (EMI/EMC testing), and environmental impact assessments. Recent strategic changes include the divestment of its diagnostic and pathological services business to Thyrocare Technologies Limited in a transaction completed in 2024 to sharpen focus on its core contract research and testing services and enhance operational efficiency. The business transfer agreement allowed Thyrocare to expand its diagnostics footprint in southern India, while Vimta Labs concentrated on strengthening its contract research offerings and regulatory services. Vimta Labs has also expanded its employee stock option plan in 2025 and its shareholding structure saw the transfer of promoter shares from Andhra Pradesh Industrial Development Corporation Limited to Telangana State Industrial Development Corporation Limited. The company operates extensively across India with its labs in Telangana and regional presences supporting global clients in pharmaceuticals, agriculture, environmental sectors, and specialty industries. Vimta Labs maintains strategic partnerships and long-term customer engagement through dedicated contract labs designed for ongoing collaborations with clients using full-time equivalent staffing models. The company's integrated service portfolio combined with recent operational streamlining positions it as a prominent scientific, technical, and regulatory partner in the Indian and international contract research and testing markets.